| Hazard Information | Back Directory | [Uses]
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma[1]. | [in vivo]
Toripalimab (0.3-10 mg/kg; i.p.; twice a week, total 6 times) exhibits substantial tumor suppressive efficacy in a dose-dependent manner[3].
| Animal Model: | A genetically modified mouse strain with human PD-1 knocked in (were subcutaneously inoculated with 1 × 106 MC38 cells)[3] | | Dosage: | 0.3, 1, 3, 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.); twice a week, total 6 times | | Result: | Inhibition of tumor growth was observed in a dose-dependent manner with substantial antitumor efficacy in 1, 3, and 10 mg/kg treatment groups.
Decreased significantly at the end of the observation period (day 23)
|
| [storage]
Store at -20°C | [References]
[1] Lin Zhang, et al. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666. DOI:10.3389/fimmu.2021.730666
[2] Keam SJ. Toripalimab: First Global Approval. Drugs. 2019 Apr;79(5):573-578. DOI:10.1007/s40265-019-01076-2
[3] Liu H, et al. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs. 2019 May/Jun;11(4):681-690. DOI:10.1080/19420862.2019.1596513 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|